Inhibition of protein kinase CK2 by quercetin enhances CD95-mediated apoptosis in a human thymus-derived T cell line

Food Research International

Volumn 63, Issue , 2014, Pages 244-251

  Russo, Maria ^a   Spagnuolo, Carmela ^a   Bilotto, Stefania ^a   Tedesco, Idolo ^a   Maiani, Giuseppe ^b   Russo, Gian Luigi ^a  

^a CNR   (Italy)

^b ISTITUTO NAZIONALE DELLA NUTRIZIONE   (Italy)

Author keywords

Apoptosis; CD95 Fas; Flavonoids; Polyphenol; Protein kinase CK2; Quercetin

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELL DEATH; DISEASES; ENZYMES; FLAVONOIDS; MONOCLONAL ANTIBODIES; PROTEINS;

ANTIOXIDANT PROPERTIES; CD95/FAS; INTRACELLULAR CONCENTRATION; POLYPHENOLS; PROTEIN KINASE CK2; QUERCETIN; SERINE-THREONINE PROTEIN KINASE; THERAPEUTIC STRATEGY;

PHENOLS;

TETRA;

EID: 84905026284     PISSN: 09639969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.foodres.2014.05.022     Document Type: Article

References (46)

1. Avila M.A., Cansado J., Harter K.W., Velasco J.A., Notario V. Quercetin as a modulator of the cellular neoplastic phenotype. Effects on the expression of mutated H-ras and p53 in rodent and human cells. Advances in Experimental Medicine and Biology 1996, 401:101-110.
2. Barata J.T. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Advances in Enzyme Regulation 2011, 51:37-49.
3. Bilotto S., Spagnuolo C., Russo M., Tedesco I., Laratta B., Russo G.L. Dietary phytochemicals in chemoprevention of cancer: An update. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2013, 13:2-24.
4. Bischoff S.C. Quercetin: Potentials in the prevention and therapy of disease. Current Opinion in Clinical Nutrition and Metabolic Care 2008, 11:733-740.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976, 72:248-254.
6. Bugianesi R., Serafini M., Simone F., Wu D., Meydani S., Ferro-Luzzi A., et al. High-performance liquid chromatography with coulometric electrode array detector for the determination of quercetin levels in cells of the immune system. Analytical Biochemistry 2000, 284:296-300.
7. Casagrande F., Darbon J.M. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: Regulation of cyclin-dependent kinases CDK2 and CDK1. Biochemical Pharmacology 2001, 61:1205-1215.
8. Guerra B., Boldyreff B., Issinger O.G. FAS-associated factor 1 interacts with protein kinase CK2 in vivo upon apoptosis induction. International Journal of Oncology 2001, 19:1117-1126.
9. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 1993, 342:1007-1011.
10. Hou D.X., Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: Direct binding and molecular modeling. Antioxidants & Redox Signaling 2010, 13:691-719.
11. Izeradjene K., Douglas L., Delaney A., Houghton J.A. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Clinical Cancer Research 2004, 10:6650-6660.
12. Jones L.J., Gray M., Yue S.T., Haugland R.P., Singer V.L. Sensitive determination of cell number using the CyQUANT cell proliferation assay. Journal of Immunological Methods 2001, 254:85-98.
13. Lamson D.W., Brignall M.S. Antioxidants and cancer, part 3: Quercetin. Alternative Medicine Review 2000, 5:196-208.
14. Lavrik I.N., Krammer P.H. Regulation of CD95/Fas signaling at the DISC. Cell Death and Differentiation 2012, 19:36-41.
15. Loke W.M., Jenner A.M., Proudfoot J.M., McKinley A.J., Hodgson J.M., Halliwell B., et al. A metabolite profiling approach to identify biomarkers of flavonoid intake in humans. The Journal of Nutrition 2009, 139:2309-2314.
16. Lolli G., Cozza G., Mazzorana M., Tibaldi E., Cesaro L., Donella-Deana A., et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry 2012, 51:6097-6107.
17. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. The American Journal of Clinical Nutrition 2005, 81:230S-242S.
18. Marshak D.R., Carroll D. Synthetic peptide substrates for casein kinase II. Methods in Enzymology 1991, 200:134-156.
19. Martins L.R., Lucio P., Silva M.C., Anderes K.L., Gameiro P., Silva M.G., et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010, 116:2724-2731.
20. Martins L.R., Lucio P., Silva M.C., Gameiro P., Silva M.G., Barata J.T. On CK2 regulation of chronic lymphocytic leukemia cell viability. Molecular and Cellular Biochemistry 2011, 356:51-55.
21. Multi-author review Protein kinase CK2 in health and disease. Cellular and Molecular Life Sciences 2009, 66:1797-1889.
22. Nguyen T.T., Tran E., Nguyen T.H., Do P.T., Huynh T.H., Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004, 25:647-659.
23. Piazza F., Manni S., Ruzzene M., Pinna L.A., Gurrieri C., Semenzato G. Protein kinase CK2 in hematologic malignancies: Reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012, 26:1174-1179.
24. Prins R.C., Burke R.T., Tyner J.W., Druker B.J., Loriaux M.M., Spurgeon S.E. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 2013, 27:2094-2096.
25. Ranelletti F.O., Maggiano N., Serra F.G., Ricci R., Larocca L.M., Lanza P., et al. Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. International Journal of Cancer 2000, 85:438-445.
26. Russo G.L., Della Pietra V., Mercurio C., Della Ragione F., Marshak D.R., Oliva A., et al. Down-regulation of protein kinase CKII activity by sodium butyrate. Biochemical and Biophysical Research Communications 1997, 233:673-677.
27. Russo M., Mupo A., Spagnuolo C., Russo G.L. Exploring death receptor pathways as selective targets in cancer therapy. Biochemical Pharmacology 2010, 80:674-682.
28. Russo M., Nigro P., Rosiello R., D'Arienzo R., Russo G.L. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia 2007, 21:1130-1133.
29. Russo M., Palumbo R., Mupo A., Tosto M., Iacomino G., Scognamiglio A., et al. Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene 2003, 22:3330-3342.
30. Russo M., Palumbo R., Tedesco I., Mazzarella G., Russo P., Iacomino G., et al. Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line. FEBS Letters 1999, 462:322-328.
31. Russo G.L., Russo M., Spagnuolo C., Tedesco I., Bilotto S., Iannitti R., et al. Quercetin: A pleiotropic kinase inhibitor against cancer. Cancer Treatment and Research 2014, 159:185-205.
32. Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochemical Pharmacology 2012, 83:6-15.
33. Russo M., Spagnuolo C., Tedesco I., Russo G.L. Phytochemicals in cancer prevention and therapy: Truth or dare?. Toxins 2010, 2:517-551.
34. Russo M., Spagnuolo C., Volpe S., Mupo A., Tedesco I., Russo G.L. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. British Journal of Cancer 2010, 103:642-648.
35. Russo M., Spagnuolo C., Volpe S., Tedesco I., Bilotto S., Russo G.L. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochemical Pharmacology 2013, 85:927-936.
36. Russo G.L., Vandenberg M.T., Yu I.J., Bae Y.S., Franza B.R., Marshak D.R. Casein kinase II phosphorylates p34cdc2 kinase in G1 phase of the HeLa cell division cycle. The Journal of Biological Chemistry 1992, 267:20317-20325.
37. Ruzzene M., Pinna L.A. Addiction to protein kinase CK2: A common denominator of diverse cancer cells?. Biochimica et Biophysica Acta 2010, 1804:499-504.
38. Ruzzene M., Tosoni K., Zanin S., Cesaro L., Pinna L.A. Protein kinase CK2 accumulation in "oncophilic" cells: Causes and effects. Molecular and Cellular Biochemistry 2011, 356:5-10.
39. Sarno S., Moro S., Meggio F., Zagotto G., Dal Ben D., Ghisellini P., et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacology & Therapeutics 2002, 93:159-168.
40. Sarno S., Reddy H., Meggio F., Ruzzene M., Davies S.P., Donella-Deana A., et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Letters 2001, 496:44-48.
41. Shehata M., Schnabl S., Demirtas D., Hilgarth M., Hubmann R., Ponath E., et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010, 116:2513-2521.
42. Spagnuolo C., Cerella C., Russo M., Chateauvieux S., Diederich M., Russo G.L. Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. British Journal of Cancer 2011, 105:221-230.
43. Spencer J.P., Kuhnle G.G., Williams R.J., Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. The Biochemical Journal 2003, 372:173-181.
44. Spencer J.P., Rice-Evans C., Williams R.J. Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. The Journal of Biological Chemistry 2003, 278:34783-34793.
45. Wang Y., Cao J., Weng J.H., Zeng S. Simultaneous determination of quercetin, kaempferol and isorhamnetin accumulated human breast cancer cells, by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 2005, 39:328-333.
46. Yu I.J., Spector D.L., Bae Y.S., Marshak D.R. Immunocytochemical localization of casein kinase II during interphase and mitosis. The Journal of Cell Biology 1991, 114:1217-1232.